(Reuters) – Bristol Myers Squibb said on Friday a trial evaluating a combination of its two cancer drugs failed to meet the primary goal to treat a type of kidney cancer.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
Bristol Myers drug combo fails to meet mail goal in kidney cancer trial
Jul 29, 2022 | 7:13 AM
